GRONINGEN, Netherlands, Feb. 11 /PRNewswire/ -- Polyganics B.V. has announced that the first patients have been enrolled in the multi-center clinical study for its degradable nasal dressing. The study is conducted by Dr. Hans Claessen (Groningen), Dr. Tjasse Bruintjes (Apeldoorn) and Dr. Maarten Majoor (Ede), all in The Netherlands. The clinical study objective is to assess intra nasal healing after application of the degradable nasal dressing at 10 and 30 days post procedure. Commercially available non-degradable nasal dressings need to be removed after several days, which is associated with strong discomfort for the patient. The Polyganics' degradable nasal dressing exhibits compressional strength comparable to the currently available non-degradable dressings but offers highly enhanced comfort to the patient as it degrades over time. After degradation, the dressing is drained from the nasal cavity. Therefore no additional removal procedure is required anymore, which avoids a painful follow-up visit for the patient. The Polyganics' nasal dressing is composed of a purely synthetic material offering maximum safety and comfort to the patient as an alternative to currently used non-degradable or animal-derived materials. The Polyganics' nasal dressing can be applied as a post-surgery nasal dressing but also to treat severe nose bleedings. If the trial is successful, Polyganics has the first commercially available nasal dressing combining strength and patient comfort, says Jan Smit (Managing Director). The global market for nasal dressings has an estimated potential of $150 million per year. The degradable nasal dressing is one of a series of medical products based on Polyganics' proprietary synthetic bioresorbable materials that exhibit superior properties and offer break-through new alternatives for e.g. animal-derived materials. The Polyganics' nasal dressing is expected to receive FDA clearance and CE Mark registration in 2003. Polyganics B.V., a privately held biomedical company based in The Netherlands, develops and manufactures medical devices based on bioresorbable biomaterials, including biodegradable surgical implants, injectable/implant drug delivery systems and bioactive coatings. Polyganics designs synthetic biomaterials and new product concepts that will be sold globally through strategic alliances and distributors. Polyganics' novel synthetic bioresorbable products strongly reduce the number of medical interventions, thereby improving patient compliance and comfort while reducing health care costs. Polyganics B.V. has its headquarters, manufacturing and research facilities in Groningen, The Netherlands. Please visit the Company's website at http://www.polyganics.com, e-mail email@example.com.
SOURCE Polyganics B.V.